Sharma, Rajiv
Dever, Daniel P. http://orcid.org/0000-0001-5966-4803
Lee, Ciaran M.
Azizi, Armon
Pan, Yidan http://orcid.org/0000-0002-9702-8530
Camarena, Joab http://orcid.org/0000-0002-3102-5820
Köhnke, Thomas
Bao, Gang http://orcid.org/0000-0001-5501-554X
Porteus, Matthew H. http://orcid.org/0000-0002-3850-4648
Majeti, Ravindra http://orcid.org/0000-0002-5814-0984
Funding for this research was provided by:
American Cancer Society (PF-18-102-01-DOC)
U.S. Department of Health & Human Services | National Institutes of Health (R01-CA188055, R01-HL142637, R01-AI097320, R01-AI120766, R01-HL135607)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Cancer Prevention and Research Institute of Texas (RR14008, RP170721)
Amon Carter Foundation and the Laurie Kraus Lacob Faculty Scholar Award in Pediatric Translational Research
Article History
Received: 6 April 2020
Accepted: 16 December 2020
First Online: 20 January 2021
Competing interests
: R.S. and D.P.D. are presently employed by Graphite Bio. M.H.P. has equity and serves on the scientific advisory board of CRISPR Therapeutics and Allogene Therapeutics. R.M. is on the Board of Directors of BeyondSpring Inc, the Scientific Advisory Boards of Zenshine Pharmaceuticals and Kodikaz Therapeutic Solutions Inc., and is an inventor on a number of patents related to CD47 cancer immunotherapy licensed to Gilead Sciences, Inc. However, none of these companies had input into the design, execution, interpretation, or publication of the work in this manuscript. Other authors declare no competing interests.